Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling -- Ignore unavailable to you. Want to Upgrade?

To: Bocor who wrote (2548)	6/24/2001 3:16:40 PM
From: Michail Shadkin	Read Replies (2) \| Respond to of 6873

Bocor - Re: IPIC They have quite a few stooge insiders. They sold between 5.05 and 6.34 only a few weeks ago. Back on dec 28, 2000 3.8 million shares were sold at 1.11 Im sure this was tax related. IPIC is in late stages of some studies, so this could be a catalyst behind this move. Also, "This agreement is a significant milestone in Interneuron's ongoing resolution of Redux-related legal actions," said Glenn L. Cooper, M.D., president and chief executive officer of Interneuron. "It represents the best interests of our shareholders and employees, and we believe it will lead to a renewed focus on Interneuron's product pipeline of multiple advanced clinical stage product candidates. "No Redux-related judgments have been brought against Interneuron to date, and with this agreement, we are confident that we have put this chapter of product liability litigation behind us," noted Dr. Cooper. "Importantly, the indemnification from AHP includes plaintiffs who have opted out of AHP's proposed national class action settlement and all plaintiffs alleging primary pulmonary hypertension. The increased insurance coverage and funding of defense costs by AHP are structured to address the relatively small number of remaining cases. We believe the result is a strengthened ability to pursue our business model of licensing and timely product development and to re-direct our attention on the outcomes of ongoing clinical testing, which include several Phase III clinical trial milestones expected to take place this year and next." cash is .88 cents but burn rate is tiny: last 2 quarters lost -.04 cents each. Here is a headline graber: "For the six months ended 3/31/01, revenues decreased 97% to $645 thousand. Net loss totaled $3.7 million vs. an income of $17.1 million" 9.80 would form a nice double top, with an easy retrace back to 9.00 level probable. Longer term looks like a reasonable short, but I would wait for the news to come first to establish longer term position. Buy the rumor and sell the news probably. Whatever the rumor is here, the insiders dont know about it. LOL Michail